



ANDA 206448

**APPROVAL**

Cipla USA, Inc.  
U.S. Agent for Cipla Limited  
9100 S. Dadeland Blvd. Suite 1500  
Miami, FL 33156  
Attention: Anand Saxena  
Regulatory Affairs

Dear Sir:

This is in reference to your abbreviated new drug application (ANDA) dated November 30, 2013, submitted pursuant to section 505(j) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), for Nevirapine Extended-release Tablets, 400 mg.

Reference is also made to your amendments dated March 7, March 19, August 12, September 23, and October 16, 2014; and February 23, April 22, July 28, July 30, and September 4, 2015.

We have completed the review of this ANDA and have concluded that adequate information has been presented to demonstrate that the drug is safe and effective for use as recommended in the submitted labeling. Accordingly the **ANDA is approved**, effective on the date of this letter. The Division of Bioequivalence has determined your Nevirapine Extended-release Tablets, 400 mg, to be bioequivalent and, therefore, therapeutically equivalent to the reference listed drug (RLD), Viramune XR Extended -release Tablets, 400 mg, of Boehringer Ingelheim Pharmaceuticals, Inc. (BI).

Your dissolution testing should be incorporated into the stability and quality control program using the same method proposed in your ANDA. The “interim” dissolution specifications are as follows:

Dissolution Testing should be conducted in:

Medium	0.04M sodium phosphate buffer pH 6.8 with 2% sodium lauryl sulfate
Volume	900 mL
Temperature	37°C ± 0.5°C
USP Apparatus	I (basket)
Speed	75 rpm

Specification(s)	2 hours: NMT	(b) (4) 0/0
	4 hours:	(b) (4) 0/0
	8 hours:	(b) (4) 0/0
	12 hours:	(b) (4) 0/0
	20 hours: NLT	(b) (4) 0/0

The “interim” dissolution test(s) and tolerances should be finalized by submitting dissolution data for the first three production size batches. Data should be submitted as a Special Supplement – Changes Being Effected when there are no revisions to the “interim” specifications or when the final specifications are tighter than the “interim” specifications. In all other instances, the information should be submitted in the form of a Prior Approval Supplement.

The RLD upon which you have based your ANDA, BI’s Viramune XR Extended-release Tablets, 400 mg, is subject to a period of patent protection. As noted in the agency's publication titled Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), U.S. Patent No. 8,460,704 (the '704 patent) is scheduled to expire on March 12, 2029.

Your ANDA contains a paragraph IV certification under section 505(j)(2)(A)(vii)(IV) of the FD&C Act stating that the '704 patent is invalid, unenforceable, or will not be infringed by your manufacture, use, or sale of Nevirapine Extended-release Tablets, 400 mg, under this ANDA. You have notified the agency that Cipla Limited (Cipla) complied with the requirements of section 505(j)(2)(B) of the FD&C Act, and that no action for infringement was brought against Cipla Limited within the statutory 45-day period.

Under section 506A of the FD&C Act, certain changes in the conditions described in this ANDA require an approved supplemental application before the change may be made.

Please note that if FDA requires a Risk Evaluation & Mitigation Strategy (REMS) for a listed drug, an ANDA citing that listed drug also will be required to have a REMS. See section 505-1(i) of the FD&C Act.

Postmarketing reporting requirements for this ANDA are set forth in 21 CFR 314.80-81 and 314.98. The Office of Generic Drugs should be advised of any change in the marketing status of this drug.

Promotional materials may be submitted to FDA for comment prior to publication or dissemination. Please note that these submissions are voluntary. If you desire comments on proposed launch promotional materials with respect to compliance with applicable regulatory requirements, we recommend you submit, in draft or mock-up form, two copies of both the promotional materials and package insert(s) directly to:

Food and Drug Administration  
Center for Drug Evaluation and Research  
Office of Prescription Drug Promotion  
5901-B Ammendale Road  
Beltsville, MD 20705

We call your attention to 21 CFR 314.81(b)(3) which requires that all promotional materials be submitted to the Office of Prescription Drug Promotion with a completed Form FDA 2253 at the time of their initial use.

You have been requested to provide information after the ANDA has been approved. Any information submitted to meet the conditions requested in this letter is considered a “Post Approval Commitment Response.” To alert the Office of Generic Drug staff to the fact that you are providing post approval commitment information, please designate your submission in your cover letter as “POST APPROVAL COMMITMENT RESPONSE.”

The Generic Drug User Fee Amendments of 2012 (GDUFA) (Public Law 112-144, Title III) established certain provisions with respect to self-identification of facilities and payment of annual facility fees. Your ANDA identifies at least one facility that is subject to the self-identification requirement and payment of an annual facility fee. Self-identification must occur by June 1 of each year for the next fiscal year. Facility fees must be paid each year by the date specified in the Federal Register notice announcing facility fee amounts. All finished dosage forms (FDFs) or active pharmaceutical ingredients (APIs) manufactured in a facility that has not met its obligations to self-identify or to pay fees when they are due will be deemed misbranded. This means that it will be a violation of federal law to ship these products in interstate commerce or to import them into the United States. Such violations can result in prosecution of those responsible, injunctions, or seizures of misbranded products. Products misbranded because of failure to self-identify or pay facility fees are subject to being denied entry into the United States.

As soon as possible, but no later than 14 days from the date of this letter, submit, using the FDA automated drug registration and listing system (eLIST), the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format, as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>, that is identical in content to the approved labeling (including the package insert, and any patient package insert and/or Medication Guide that may be required). Information on submitting SPL files using eLIST may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As” at <http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>. The SPL will be accessible via publicly available labeling repositories.

Sincerely yours,

**Carol A. Holquist -S**

Digitally signed by Carol A. Holquist -S  
DN: c=US, o=U.S. Government, ou=HHS, ou=FDA, ou=People,  
0.9.2342.19200300.100.1.1=1300052464, cn=Carol A. Holquist -S  
Date: 2015.10.15 23:39:22 -04'00'

Carol A. Holquist, RPh  
Acting Deputy Director  
Office of Regulatory Operations  
Office of Generic Drugs  
Center for Drug Evaluation and Research